Love Katie M, Brown Joshua B, Harbrecht Brian G, Muldoon Susan B, Miller Keith R, Benns Matthew V, Smith Jason W, Baker Christopher E, Franklin Glen A
From the Department of Surgery (K.M.L., C.C.B.), Virginia Tech Carilion School of Medicine, Roanoke, VA; Department of Surgery (K.M.L., B.G.H., K.R.M., M.V.B., J.W.S., G.A.F.), University of Louisville School of Medicine, Louisville, KY; Department of Surgery (J.B.B.), University of Pittsburgh, Pittsburgh, PA; University of Louisville School of Public Health and Information Sciences (K.M.L., S.B.M.).
J Trauma Acute Care Surg. 2016 May;80(5):792-8. doi: 10.1097/TA.0000000000000984.
Survival after traumatic cardiopulmonary arrest (TCPA) is rare and requires significant resource expenditure. Organ donation as an outcome of TCPA resuscitation has not yet been included in a cost analysis. The aims of this study were to identify variables associated with survival and organ donation after TCPA, and to estimate the cost of achieving these outcomes. We hypothesized that the inclusion of organ donation as a potential outcome would make TCPA resuscitation more cost-effective.
Adult patients who required resuscitation for TCPA at a level I trauma center were retrospectively reviewed over 36 months. Data were obtained from medical records, hospital accounting records, and the local organ procurement agency. Outcomes included survival to discharge, neurologic function, and organ donor eligibility. An individual-level state-transition cost-effectiveness model was used to evaluate the cost of TCPA resuscitation with and without organ donation included as an outcome. Incremental cost-effectiveness ratio was calculated to determine additional cost per life saved when organ donation is included.
Over the study period, 8,932 subjects were evaluated. Traumatic cardiopulmonary arrest occurred in 237 patients (3%). The mortality rate was 97%. Variables associated with survival included emergency department disposition to the operating room (p < 0.01) and reactive pupils (p < 0.001). Of seven survivors, four were discharged neurologically intact. Of the patients with TCPA, 5% were eligible for organ donation with a procurement rate of 2%. Organ donor eligibility was associated with arrest after arrival to the emergency department (p < 0.01) and transfusion of fresh frozen plasma (p = 0.01). The cost of TCPA resuscitation per survivor was $1.8 million; cost per survivor or life saved by donation was $538,000. The incremental cost-effectiveness ratio was $76,816 per additional life saved including donation as an outcome.
The decision to pursue resuscitation should continue to be based on the presence of signs of life, especially pupil reactivity and duration of arrest. If the primary objective is survival, organ procurement will be maximized without conflict of interest. Early fresh frozen plasma transfusion may increase successful organ donation. The financial burden of TCPA resuscitation can be mitigated by expanding end points to include organ donation.
Prognostic and epidemiologic study, level III; cost analysis, level V.
创伤性心肺骤停(TCPA)后的存活情况罕见,且需要大量资源投入。作为TCPA复苏结果的器官捐赠尚未纳入成本分析。本研究的目的是确定与TCPA后存活和器官捐赠相关的变量,并估算实现这些结果的成本。我们假设将器官捐赠作为一种潜在结果纳入会使TCPA复苏更具成本效益。
对一家一级创伤中心36个月内需要进行TCPA复苏的成年患者进行回顾性研究。数据来自医疗记录、医院账目记录以及当地器官获取机构。结果包括出院存活、神经功能以及器官捐赠资格。使用个体水平的状态转换成本效益模型来评估将器官捐赠作为结果和不将其作为结果时TCPA复苏的成本。计算增量成本效益比以确定纳入器官捐赠时每挽救一条生命的额外成本。
在研究期间,共评估了8932名受试者。237名患者(3%)发生了创伤性心肺骤停。死亡率为97%。与存活相关的变量包括急诊室转至手术室的情况(p<0.01)和瞳孔反应(p<0.001)。7名幸存者中,4人出院时神经功能完好。在TCPA患者中,5%符合器官捐赠资格,获取率为2%。器官捐赠资格与到达急诊科后发生骤停(p<0.01)和输注新鲜冰冻血浆(p=0.01)相关。每名存活者的TCPA复苏成本为180万美元;通过捐赠挽救的每名存活者或每条生命的成本为53.8万美元。将捐赠作为结果时,每多挽救一条生命的增量成本效益比为76816美元。
进行复苏的决定应继续基于生命体征的存在,尤其是瞳孔反应和骤停持续时间。如果主要目标是存活,器官获取将在不产生利益冲突的情况下最大化。早期输注新鲜冰冻血浆可能会增加器官捐赠的成功率。通过扩大终点以包括器官捐赠,可以减轻TCPA复苏的经济负担。
预后和流行病学研究,III级;成本分析,V级。